License Agreements and Clinical Research Support Agreements (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2017 |
Jun. 30, 2016 |
Jun. 30, 2017 |
Jun. 30, 2016 |
|
| Research and development - licenses acquired | $ 1,500 | $ 0 | $ 2,075 | $ 0 |
| IL-13 [Member] | ||||
| Research and development - licenses acquired | 0 | 0 | 250 | 0 |
| IV/ICV [Member] | ||||
| Research and development - licenses acquired | 0 | 0 | 125 | 0 |
| PSCA [Member] | ||||
| Research and development - licenses acquired | 300 | 0 | 300 | 0 |
| HER2 [Member] | ||||
| Research and development - licenses acquired | 600 | 0 | 600 | 0 |
| CS1 [Member] | ||||
| Research and development - licenses acquired | 600 | 0 | 600 | 0 |
| UCLA [Member] | ||||
| Research and development - licenses acquired | $ 0 | $ 0 | $ 200 | $ 0 |
| X | ||||||||||
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|